Twist Bioscience Corp
$ 32.81
5.26%
04 Dec - close price
- Market Cap 1,905,984,000 USD
- Current Price $ 32.81
- High / Low $ 33.21 / 30.42
- Stock P/E N/A
- Book Value 7.80
- EPS -1.37
- Next Earning Report 2026-01-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.14 %
- ROE -0.16 %
- 52 Week High 55.33
- 52 Week Low 23.30
About
Twist Bioscience Corporation (TWST) is a leading innovator in the synthetic biology landscape, specializing in the design and high-volume production of synthetic DNA products tailored for various sectors including pharmaceuticals, agriculture, and industrial biotechnology. Headquartered in South San Francisco, California, the company leverages its proprietary DNA synthesis technology to deliver scalable and cost-effective solutions that address the evolving needs of its diverse customer base. With a strong focus on research and development, Twist is poised to drive significant advancements in genetic discovery and application, solidifying its pivotal role in the transformative field of synthetic biology.
Analyst Target Price
$35.62
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-17 | 2025-08-04 | 2025-05-05 | 2025-02-03 | 2024-11-18 | 2024-08-02 | 2024-05-02 | 2024-02-02 | 2023-11-17 | 2023-08-04 | 2023-05-05 | 2023-02-03 |
| Reported EPS | -0.45 | -0.47 | -0.66 | -0.53 | -0.59 | -1.47 | -0.79 | -0.75 | -0.81 | -0.78 | -1.04 | -0.74 |
| Estimated EPS | -0.5 | -0.57 | -0.56 | -0.63 | -0.7 | -0.77 | -0.82 | -0.78 | -0.92 | -1.14 | -1.12 | -1.13 |
| Surprise | 0.05 | 0.1 | -0.1 | 0.1 | 0.11 | -0.7 | 0.03 | 0.03 | 0.11 | 0.36 | 0.08 | 0.39 |
| Surprise Percentage | 10% | 17.5439% | -17.8571% | 15.873% | 15.7143% | -90.9091% | 3.6585% | 3.8462% | 11.9565% | 31.5789% | 7.1429% | 34.5133% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-01-30 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.4256 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TWST
2025-10-14 05:23:19
Twist Bioscience (NASDAQ:TWST) stock fell 4.4% following insider selling, specifically by CFO Adam Nau. Analysts have set new price targets, with Cowen reiterating a "buy" rating and Evercore ISI reducing its target to $42.00 but maintaining an "outperform" rating. Institutional investors have significantly altered their stakes in the company, with several increasing their holdings.
2025-10-11 21:00:54
Twist Bioscience CFO Adam Laponis sold 2,517 shares of the company's stock for approximately $82,860, reducing his total ownership to 91,525 shares. This sale follows previous transactions in which Laponis sold additional shares in early October. The company's stock experienced a 2.2% decline, trading at $31.19, while analysts maintain a "Moderate Buy" rating with an average price target of $48.50.
2025-10-11 21:00:52
Twist Bioscience CFO Adam Laponis sold 3,000 shares of the company's stock at an average price of $31.15, reducing his ownership by 3.09%. This sale is part of a series of recent transactions by Laponis, occurring as TWST stock experienced a 2.2% decline. The article details the financial performance of Twist Bioscience and analyst ratings, which currently indicate a "Moderate Buy" with a consensus target price of $48.50.
2023-11-17 15:51:42
Twist Bioscience introduced its new “Express Genes” synthesis service, promising a 5 to 7 business day turnaround for manufactured DNA, significantly faster than competitors. This acceleration is attributed to their proprietary silicon chip technology and increased capacity at their Wilsonville facility. The announcement comes amidst past scrutiny from an activist short-seller, Scorpion Capital, which had previously claimed Twist's technology was inefficient and led to a "cash-burning inferno."
2022-11-15 21:43:00
Twist Bioscience shares fell 20% after a short-seller report from Scorpion Capital compared the company to Theranos, labeling it a "cash-burning inferno" and a “‘synthetic biology’ swindle.” The report was based on interviews with former executives, employees, customers, and competitors, as well as a field visit to the company’s Oregon facility. Scorpion Capital suggests the stock could drop to zero.
2022-10-27 18:57:31
Twist Bioscience has promoted Patrick Finn, Ph.D., to the newly created position of president and chief operating officer. Dr. Finn, who previously served as chief commercial officer, is credited with significantly growing sales and will now oversee both commercial and operations teams. This promotion reflects his increasing responsibility and the company's expansion plans, including a focus on customer experience, product quality, and fiscal responsibility.
